Genmab A/S (GNMSF)
OTCMKTS
· Delayed Price · Currency is USD
214.95
0.00 (0.00%)
Jul 14, 2025, 4:00 PM EDT
Genmab Revenue
Genmab had revenue of $715.00M in the quarter ending March 31, 2025, with 18.57% growth. This brings the company's revenue in the last twelve months to $3.23B, up 25.43% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
3.23B
Revenue Growth
+25.43%
P/S Ratio
4.03
Revenue / Employee
1.22M
Employees
2,682
Market Cap
13.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
| Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
| Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
| Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
| Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Genmab News
- 14 days ago - Genmab Announces Changes to its Executive Committee - GlobeNewsWire
- 15 days ago - Completion of Share Buy-back Program - GlobeNewsWire
- 22 days ago - Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One - Seeking Alpha
- 22 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 4 weeks ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 4 weeks ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire
- 4 weeks ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 4 weeks ago - Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) - Business Wire